Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion issued a re-disclosure regarding media reports on its planned KRW 300.0B plant investment in Yesan, South Chungcheong Province, stating that a Memorandum of Agreement (MOA) for a drug product (DP) facility was signed in February and details remain under discussion.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Clarification of Rumors or Reports (Unconfirmed)
- Target Rumor / Media Outlet: Seoul Economic Daily (2023-12-01 print edition) and other media outlets
- Reported Content: Reports stating “Celltrion to build South Chungcheong plant, investing KRW 300.0B by 2028”
- Clarification Details:
- November 30, 2023: Signed a Memorandum of Understanding (MOU) with Yesan-gun, South Chungcheong Province for a KRW 300.0B biopharmaceutical & ancillary materials facility by December 2028
- February 27, 2025: Signed a Memorandum of Agreement (MOA) with South Chungcheong Province, Yesan-gun, and Chungnam Development Corporation for a KRW 300.0B Drug Product (DP) facility
- Specific investment terms including duration and total amount remain subject to change upon ongoing negotiations
- Expected Re-disclosure Date: February 26, 2026 (or upon finalization of specific details within 6 months)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Investment Decision and Re-disclosure Status for Yesan DP Facility
This disclosure provides an update on Celltrion’s proposed Drug Product (DP) manufacturing facility in Yesan, South Chungcheong Province following the signing of an MOA, making it important to monitor the finalization of definitive investment plans. Tracking the transition from an MOA to a binding capital expenditure commitment confirms progress on domestic manufacturing infrastructure expansion. Finalized investment terms and updates can be verified through future clarification disclosures or progress filings expected prior to February 26, 2026.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
